NCT06776250View on ClinicalTrials.gov

Study of How Safe and Effective Tarlatamab is in Brain Cancers

PHASE2RecruitingINTERVENTIONAL

Enrollment

44

Participants

Timeline

Start Date

August 18, 2025

Primary Completion Date

March 3, 2028

Study Completion Date

March 3, 2028

Conditions

Astrocytic TumorOligodendroglial Tumor

Interventions

DRUG

Tarlatamab

Tarlatamab is a BiTE molecule designed to direct T effector cells toward DLL3-expressing cells.

Trial Locations (1)

M5G 2M9

RECRUITING

Princess Margaret Cancer Centre, Toronto

Sponsors

Collaborators (1)

All Listed Sponsors

collaborator

Amgen

INDUSTRY

lead

University Health Network, Toronto

OTHER